Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (191)	5/18/2000 12:38:00 PM
From: Jim Oravetz	Read Replies (2) of 370

Vion Initiates Phase I Continuous Infusion Trial of Anticancer Agent Triapine(R) At Albert Einstein College of Medicine/Montefiore Medical Center NEW HAVEN, Conn., May 18 /PRNewswire/ -- Vion Pharmaceuticals, Inc. (Nasdaq: VION) today announced it initiated an additional Phase I study of Triapine(R) to assess the safety and maximum tolerated dose when administered intravenously, by continuous infusion, over a 96-hour period. The trial will be conducted at the Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, under the direction of Drs. Scott Wadler and Della Makower. This new study follows the completion of a Phase I single dose study of Triapine, which demonstrated its safety profile and ability to reach pharmacologically relevant serum concentrations. The current trial, and an ongoing study of short infusions administered daily for 5 days, will continue to evaluate the safety profile and feasibility of extending injections of Triapine over several days, which, in preclinical animal tumor models, demonstrated Triapine's greatest antitumor activity siliconinvestor.com Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next